ArticleBMC musculoskeletal disorders2025
Efficacy and safety study of tranexamic acid combined with low-molecular-weight heparin and nadroparin calcium in postoperative application after joint replacement: a retrospective cohort study.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative study of femoral neck shortening following two types of internal fixation in young and middle-aged patients with displaced femoral neck fractures.Frontiers in surgery · 2026Article
- Efficacy and safety of epsilon-aminohexanoic acid and tranexamic acid during posterior interbody fusion surgery.Frontiers in surgery · 2025Article
- Efficacy and safety of tranexamic acid combined with low molecular weight heparin versus fondaparinux sodium following total knee arthroplasty: a retrospective cohort study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-molecular-weight heparin (LMWH) and nadroparin calcium are commonly used to prevent deep vein thrombosis (DVT) following joint replacement surgery. In this study, we compared the effects of tranexamic acid combined with either LMWH or nadroparin calcium in preventing DVT after joint replacement surgery.
methodsA retrospective analysis was conducted on patients who underwent unilateral THA/TKA at the Sixth Affiliated Hospital of Xinjiang Medical University from September 2021 to June 2023. Patients were divided into two groups based on the anticoagulant used: Tranexamic Acid + Low-Molecular-Weight Heparin group (n = 80) and Tranexamic Acid + Nadroparin Calcium group (n = 85), both treated for 2 weeks. The perioperative indicators [blood loss, hospital stay, operation time, transfusion rate, transfusion volume, and total hospitalization cost], complications DVT, muscle compartment vein thrombosis (MCVT), incision infection, pulmonary thromboembolism, and postoperative hematoma], coagulation indicators [D-dimer, prothrombin activity, international normalized ratio, and fibrinogen], hematological parameters [platelets, hemoglobin, hematocrit], and inflammatory factors [procalcitonin (PCT), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor (TNF-α)] were compared between the two groups.
resultThe preoperative indicators of both groups were statistically indistinguishable (P > 0.05). Comparisons of intraoperative blood loss, overt blood loss, covert blood loss, total blood loss, hospital stay duration, operation time, transfusion rate, and transfusion volume showed no significant differences between the groups (P > 0.05). The TXA + LMWH group exhibited significantly lower D-dimer, PT activity, international normalized ratio, and fibrinogen levels on postoperative days 1 and 5 compared to the TXA + Nadroparine group, with significant differences observed (P < 0.05). No significant differences between the two groups were found in platelet count, hemoglobin, hematocrit, PCT, IL-6, IL-8, and TNF-α levels on postoperative days 1 and 5 (P > 0.05). The total hospitalization costs in the TXA + LMWH group were significantly lower than those in the TXA + Nadroparine group, with a significant difference (P < 0.05).
conclusionThis study found that the clinical efficacy and safety of the TXA + Nadroparine and TXA + LMWH groups were basically the same after joint replacement surgery. However, the TXA + LMWH group demonstrated better prevention of thrombosis and significantly lower overall hospitalization costs compared to the TXA + Nadroparine group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.